Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease

Gut

Volumn 54, Issue 9, 2005, Pages 1237-1243

  Halfvarson, J ^a   Standaert Vitse, A ^b   Jarnerot G ^a   Sendid, B ^b   Jouault, T ^b   Bodin, L ^a   Duhamel, A ^b   Colombel, J F ^b   Tysk, C ^a   Poulain, D ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FUNGUS ANTIBODY; SACCHAROMYCES CEREVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROHN DISEASE; DIZYGOTIC TWINS; FEMALE; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOZYGOTIC TWINS; PHENOTYPE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIBLING; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, FUNGAL; BIOLOGICAL MARKERS; CONFIDENCE INTERVALS; DISEASES IN TWINS; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINE, SMALL; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; SACCHAROMYCES CEREVISIAE; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC;

EID: 23944516248     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.066860     Document Type: Article

References (43)

1. Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42:788-91.
2. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
3. Walker U, Aldhous MC, Drummond HE, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004;135:490-6.
4. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-24.
5. Russell RK, Satsangi J. IBD: a family affair. Best Pract Res Clin Gastroenterol 2004;18:525-39.
6. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol 1998;93:1306-10.
7. Seibold F, Stich O, Hufnagl R, et al. Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family study. Scand J Gastroenterol 2001;36:196-201.
8. Sutton CL, Yang H, Li Z, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 2000;46:58-63.
9. Vermeire S, Peeters M, Vlietinck R, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis 2001;7:8-15.
10. Tysk C, Lindberg E, Järnerot G, et al. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988;29:990-6.
11. Halfvarson J, Bodin L, Tysk C, et al. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003;124:1767-73.
12. Halfvarson J, Tysk C, Järnerot G. Decreasing pair concordance in monozygotic twins with Crohns disease. Gastroenterology 2004;126(suppl 2):A45.
13. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
14. Cederlöf R, Friberg L, Jonsson E, et al. Studies on similarity diagnosis in twins with the aid of mailed questionnaires. Acta Genet 1961;11:338-62.
15. Lichtenstein P, De Faire U, Floderus B, et al. The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med 2002;252:184-205.
16. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996;3:219-26.
17. Halfvarson J, Bresso F, Tysk C, et al. Genetic Crohn's disease. A different entity than sporadic. A study in monozygotic twins. Gastroenterology 2004;126(suppl 2):A359.
18. Halfvarson J, Daperno M, Ahmad T, et al. Influene of CARD15/NOD2 and IBD5 in Swedish dizygotic twins (Swedish). Sv Läkarsällskapets Handl Hygiea 2003;112:168.
19. Brown H, Prescott R. Applied mixed models in medicine. Chichester, UK: John Wiley and Sons, 1999:199-235.
20. Bland JM, Altman DG. Statistics notes: The use of transformation when comparing two means. BMJ 1996;312:1153.
21. Dunn G. Design and analysis of reliability studies. The statistical evaluation of measurement errors. New York: Oxford University Press, 1989:34-5.
22. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988;297:1105-6.
23. Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115:822-9.
24. Peelers M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96:730-4.
25. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
26. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
27. Ahmad T, Tamboli CP, Jewell D, et al. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 2004;126:1533-49.
28. Arnott ID, Nimmo ER, Drummond HE, et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004;5:417-25.
29. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002;359:1661-5.
30. Helio T, Halme L, Lappalainen M, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003;52:558-62.
31. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66.
32. Vermeire S, Louis E, Rutgeerts P, et al. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002;123:106-11.
33. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867-74.
34. Vermeire S, Wild G, Kocher K, et al. CARD15 genetic variation in a Quebec population: prevalence, genotype-phenotype relationship, and haplotype structure. Am J Hum Genet 2002;71:74-83.
35. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-88.
36. Zhou Z, Lin XY, Akolkar PN, et al. Variation at NOD2/CARD15 in familial and sporadic cases of Crohn's disease in the Ashkenazi Jewish population. Am J Gastroenterol 2002;97:3095-101.
37. Sugimura K, Taylor KD, Lin YC, et al. A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews. Am J Hum Genet 2003;72:509-18.
38. Bonen DK, Ogura Y, Nicolae DL, et al. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003; 124:140-6.
39. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
40. Radlmayr M, Torok HP, Martin K, et al. The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn's disease. Gastroenterology 2002;122:2091-2.
41. Dubinsky M, Lee-Uy N, Lin Y-C, et al. Synergism of NOD2/CARD15 and ASCA (anti-Saccharomyces cerevisiae antibodies) contributes to disease behavior in pediatric Crohn's disease (CD) patients. Gastroenterology 2003;124(suppl 1):A372.
42. Esters N, Pierik M, van Steen K, et al. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am J Gastroenterol 2004;99:299-305.
43. Seibold F, Konrad A, Flogerzi B, et al. Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn's disease. Gastroenterology 2004;127:1076-84.